Detalhe da pesquisa
1.
Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer.
BJU Int;
128(6): 713-721, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33793062
2.
A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.
J Urol;
196(3): 747-54, 2016 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26968644
3.
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
Support Care Cancer;
24(3): 1327-37, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26329397
4.
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Lancet;
379(9821): 1103-11, 2012 Mar 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22277570
5.
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
Lancet;
379(9810): 39-46, 2012 Jan 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22093187
6.
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Support Care Cancer;
21(12): 3497-507, 2013 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23975226
7.
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
N Engl J Med;
361(8): 745-55, 2009 Aug 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19671656
8.
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
J Urol;
183(5): 1892-8, 2010 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20303119
9.
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
J Urol;
182(6): 2670-5, 2009 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19836774
10.
A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis.
BJU Int;
103(1): 56-60, 2009 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18778342
11.
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Neurology;
91(7): e657-e665, 2018 08 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30030330
12.
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Eur Urol;
63(3): 496-503, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23098762
13.
Sarcopenia during androgen-deprivation therapy for prostate cancer.
J Clin Oncol;
30(26): 3271-6, 2012 Sep 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22649143
14.
Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Eur Urol;
59(5): 747-54, 2011 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21129846
15.
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
J Bone Miner Res;
26(12): 2827-33, 2011 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21898590
16.
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.
Can Urol Assoc J;
4(2): 129-35, 2010 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20368898
17.
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Eur Urol;
52(1): 106-14, 2007 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17270340